APO Research
Talk to an analyst

APO RESEARCH · REPORT

Therapeutic Nuclear Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Therapeutic Nuclear Drug Market Outlook and Growth Opportunities 2026

2 January 2026193 pages

Choose your research edition.

Industry ResearchTherapeutic Nuclear Drug Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Therapeutic Nuclear Drug Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Therapeutic Nuclear Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Therapeutic Nuclear Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Therapeutic Nuclear Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Therapeutic Nuclear Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Therapeutic Nuclear Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Therapeutic Nuclear Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Therapeutic Nuclear Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Therapeutic Nuclear Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Therapeutic Nuclear Drug market include Novartis, Dongcheng, Bayer, Q BioMed, Mundipharma, Lantheus, Jubilant Radiopharma, International Isotopes and Curium Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Therapeutic Nuclear Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Therapeutic Nuclear Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Therapeutic Nuclear Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Therapeutic Nuclear Drug market.

Therapeutic Nuclear Drug Segment by Company

Novartis

Dongcheng

Bayer

Q BioMed

Mundipharma

Lantheus

Jubilant Radiopharma

International Isotopes

Curium Pharmaceuticals

China Isotope & Radiation

Aurobindo Pharma

Therapeutic Nuclear Drug Segment by Type

Lutetium-177

Radium-223

Iodine-131

Other

Therapeutic Nuclear Drug Segment by Application

Lymphoma

Thyroid

Bone Metastasis

Other

Therapeutic Nuclear Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Therapeutic Nuclear Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Therapeutic Nuclear Drug key companies, revenue, market share, and recent developments.

3. To split the Therapeutic Nuclear Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Therapeutic Nuclear Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Therapeutic Nuclear Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Therapeutic Nuclear Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Nuclear Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Nuclear Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Nuclear Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Therapeutic Nuclear Drug industry.

Chapter 3: Detailed analysis of Therapeutic Nuclear Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Therapeutic Nuclear Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Therapeutic Nuclear Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Therapeutic Nuclear Drug Industry Trends Table 2. Therapeutic Nuclear Drug Industry Drivers Table 3. Therapeutic Nuclear Drug Industry Opportunities and Challenges Table 4. Therapeutic Nuclear Drug Industry Restraints Table 5. Global Therapeutic Nuclear Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Therapeutic Nuclear Drug Revenue Share by Company (2021-2026) Table 7. Global Therapeutic Nuclear Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Therapeutic Nuclear Drug Key Company Manufacturing Base & Headquarters Table 9. Global Therapeutic Nuclear Drug Company, Product Type & Application Table 10. Global Therapeutic Nuclear Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Therapeutic Nuclear Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Lutetium-177 Table 15. Significant Companies of Radium-223 Table 16. Significant Companies of Iodine-131 Table 17. Significant Companies of Other Table 18. Global Therapeutic Nuclear Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Therapeutic Nuclear Drug Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Therapeutic Nuclear Drug Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Therapeutic Nuclear Drug Sales Value Share by Type (2021-2026) Table 22. Global Therapeutic Nuclear Drug Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Lymphoma Table 24. Significant Companies of Thyroid Table 25. Significant Companies of Bone Metastasis Table 26. Significant Companies of Other Table 27. Global Therapeutic Nuclear Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Therapeutic Nuclear Drug Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Therapeutic Nuclear Drug Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Therapeutic Nuclear Drug Sales Value Share by Application (2021-2026) Table 31. Global Therapeutic Nuclear Drug Sales Value Share by Application (2027-2032) Table 32. Global Therapeutic Nuclear Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Therapeutic Nuclear Drug Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Therapeutic Nuclear Drug Sales Value Share by Region (2021-2026) Table 35. Global Therapeutic Nuclear Drug Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Therapeutic Nuclear Drug Sales Value Share by Region (2027-2032) Table 37. Global Therapeutic Nuclear Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Therapeutic Nuclear Drug Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Therapeutic Nuclear Drug Sales Value Market Share by Country (2021-2026) Table 40. Global Therapeutic Nuclear Drug Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Therapeutic Nuclear Drug Sales Value Market Share by Country (2027-2032) Table 42. Novartis Company Information Table 43. Novartis Business Overview Table 44. Novartis Therapeutic Nuclear Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Novartis Therapeutic Nuclear Drug Product Portfolio Table 46. Novartis Recent Development Table 47. Dongcheng Company Information Table 48. Dongcheng Business Overview Table 49. Dongcheng Therapeutic Nuclear Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Dongcheng Therapeutic Nuclear Drug Product Portfolio Table 51. Dongcheng Recent Development Table 52. Bayer Company Information Table 53. Bayer Business Overview Table 54. Bayer Therapeutic Nuclear Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Bayer Therapeutic Nuclear Drug Product Portfolio Table 56. Bayer Recent Development Table 57. Q BioMed Company Information Table 58. Q BioMed Business Overview Table 59. Q BioMed Therapeutic Nuclear Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Q BioMed Therapeutic Nuclear Drug Product Portfolio Table 61. Q BioMed Recent Development Table 62. Mundipharma Company Information Table 63. Mundipharma Business Overview Table 64. Mundipharma Therapeutic Nuclear Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Mundipharma Therapeutic Nuclear Drug Product Portfolio Table 66. Mundipharma Recent Development Table 67. Lantheus Company Information Table 68. Lantheus Business Overview Table 69. Lantheus Therapeutic Nuclear Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Lantheus Therapeutic Nuclear Drug Product Portfolio Table 71. Lantheus Recent Development Table 72. Jubilant Radiopharma Company Information Table 73. Jubilant Radiopharma Business Overview Table 74. Jubilant Radiopharma Therapeutic Nuclear Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Jubilant Radiopharma Therapeutic Nuclear Drug Product Portfolio Table 76. Jubilant Radiopharma Recent Development Table 77. International Isotopes Company Information Table 78. International Isotopes Business Overview Table 79. International Isotopes Therapeutic Nuclear Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. International Isotopes Therapeutic Nuclear Drug Product Portfolio Table 81. International Isotopes Recent Development Table 82. Curium Pharmaceuticals Company Information Table 83. Curium Pharmaceuticals Business Overview Table 84. Curium Pharmaceuticals Therapeutic Nuclear Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Curium Pharmaceuticals Therapeutic Nuclear Drug Product Portfolio Table 86. Curium Pharmaceuticals Recent Development Table 87. China Isotope & Radiation Company Information Table 88. China Isotope & Radiation Business Overview Table 89. China Isotope & Radiation Therapeutic Nuclear Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. China Isotope & Radiation Therapeutic Nuclear Drug Product Portfolio Table 91. China Isotope & Radiation Recent Development Table 92. Aurobindo Pharma Company Information Table 93. Aurobindo Pharma Business Overview Table 94. Aurobindo Pharma Therapeutic Nuclear Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Aurobindo Pharma Therapeutic Nuclear Drug Product Portfolio Table 96. Aurobindo Pharma Recent Development Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. Therapeutic Nuclear Drug Product Image Figure 2. Global Therapeutic Nuclear Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Therapeutic Nuclear Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Therapeutic Nuclear Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Lutetium-177 Image Figure 8. Radium-223 Image Figure 9. Iodine-131 Image Figure 10. Other Image Figure 11. Global Therapeutic Nuclear Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Therapeutic Nuclear Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Therapeutic Nuclear Drug Sales Value Share by Type (2021-2032) Figure 14. Lymphoma Image Figure 15. Thyroid Image Figure 16. Bone Metastasis Image Figure 17. Other Image Figure 18. Global Therapeutic Nuclear Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Therapeutic Nuclear Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Therapeutic Nuclear Drug Sales Value Share by Application (2021-2032) Figure 21. Global Therapeutic Nuclear Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Therapeutic Nuclear Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Therapeutic Nuclear Drug Sales Value (2021-2032) & (US$ Million) Figure 24. North America Therapeutic Nuclear Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Therapeutic Nuclear Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Therapeutic Nuclear Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Therapeutic Nuclear Drug Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Therapeutic Nuclear Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Therapeutic Nuclear Drug Sales Value (2021-2032) & (US$ Million) Figure 30. South America Therapeutic Nuclear Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Therapeutic Nuclear Drug Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Therapeutic Nuclear Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Lutetium-177
  • Radium-223
  • Iodine-131
  • Other
Applications
  • Lymphoma
  • Thyroid
  • Bone Metastasis
  • Other
Companies covered
  • Novartis
  • Dongcheng
  • Bayer
  • Q BioMed
  • Mundipharma
  • Lantheus
  • Jubilant Radiopharma
  • International Isotopes
  • Curium Pharmaceuticals
  • China Isotope & Radiation
  • Aurobindo Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Therapeutic Nuclear Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Therapeutic Nuclear Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Therapeutic Nuclear Drug Market Dynamics
  1. 2.1 Therapeutic Nuclear Drug Industry Trends
  2. 2.2 Therapeutic Nuclear Drug Industry Drivers
  3. 2.3 Therapeutic Nuclear Drug Industry Opportunities and Challenges
  4. 2.4 Therapeutic Nuclear Drug Industry Restraints
3 Therapeutic Nuclear Drug Market by Company
  1. 3.1 Global Therapeutic Nuclear Drug Company Revenue Ranking in 2025
  2. 3.2 Global Therapeutic Nuclear Drug Revenue by Company (2021-2026)
  3. 3.3 Global Therapeutic Nuclear Drug Company Ranking (2024-2026)
  4. 3.4 Global Therapeutic Nuclear Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Therapeutic Nuclear Drug Company Product Type and Application
  6. 3.6 Global Therapeutic Nuclear Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Therapeutic Nuclear Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Therapeutic Nuclear Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Therapeutic Nuclear Drug Market by Type
  1. 4.1 Therapeutic Nuclear Drug Type Introduction
  2. 4.1.1 Lutetium-177
  3. 4.1.2 Radium-223
  4. 4.1.3 Iodine-131
  5. 4.1.4 Other
  6. 4.2 Global Therapeutic Nuclear Drug Sales Value by Type
  7. 4.2.1 Global Therapeutic Nuclear Drug Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Therapeutic Nuclear Drug Sales Value by Type (2021-2032)
  9. 4.2.3 Global Therapeutic Nuclear Drug Sales Value Share by Type (2021-2032)
5 Therapeutic Nuclear Drug Market by Application
  1. 5.1 Therapeutic Nuclear Drug Application Introduction
  2. 5.1.1 Lymphoma
  3. 5.1.2 Thyroid
  4. 5.1.3 Bone Metastasis
  5. 5.1.4 Other
  6. 5.2 Global Therapeutic Nuclear Drug Sales Value by Application
  7. 5.2.1 Global Therapeutic Nuclear Drug Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Therapeutic Nuclear Drug Sales Value by Application (2021-2032)
  9. 5.2.3 Global Therapeutic Nuclear Drug Sales Value Share by Application (2021-2032)
6 Therapeutic Nuclear Drug Regional Value Analysis
  1. 6.1 Global Therapeutic Nuclear Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Therapeutic Nuclear Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Therapeutic Nuclear Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Therapeutic Nuclear Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Therapeutic Nuclear Drug Sales Value (2021-2032)
  7. 6.3.2 North America Therapeutic Nuclear Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Therapeutic Nuclear Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Therapeutic Nuclear Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Therapeutic Nuclear Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Therapeutic Nuclear Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Therapeutic Nuclear Drug Sales Value (2021-2032)
  16. 6.6.2 South America Therapeutic Nuclear Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Therapeutic Nuclear Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Therapeutic Nuclear Drug Sales Value Share by Country, 2025 VS 2032
7 Therapeutic Nuclear Drug Country-level Value Analysis
  1. 7.1 Global Therapeutic Nuclear Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Therapeutic Nuclear Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Therapeutic Nuclear Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Therapeutic Nuclear Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Therapeutic Nuclear Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Therapeutic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Therapeutic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Therapeutic Nuclear Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Therapeutic Nuclear Drug Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Dongcheng
  8. 8.2.1 Dongcheng Company Information
  9. 8.2.2 Dongcheng Business Overview
  10. 8.2.3 Dongcheng Therapeutic Nuclear Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Dongcheng Therapeutic Nuclear Drug Product Portfolio
  12. 8.2.5 Dongcheng Recent Developments
  13. 8.3 Bayer
  14. 8.3.1 Bayer Company Information
  15. 8.3.2 Bayer Business Overview
  16. 8.3.3 Bayer Therapeutic Nuclear Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bayer Therapeutic Nuclear Drug Product Portfolio
  18. 8.3.5 Bayer Recent Developments
  19. 8.4 Q BioMed
  20. 8.4.1 Q BioMed Company Information
  21. 8.4.2 Q BioMed Business Overview
  22. 8.4.3 Q BioMed Therapeutic Nuclear Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Q BioMed Therapeutic Nuclear Drug Product Portfolio
  24. 8.4.5 Q BioMed Recent Developments
  25. 8.5 Mundipharma
  26. 8.5.1 Mundipharma Company Information
  27. 8.5.2 Mundipharma Business Overview
  28. 8.5.3 Mundipharma Therapeutic Nuclear Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Mundipharma Therapeutic Nuclear Drug Product Portfolio
  30. 8.5.5 Mundipharma Recent Developments
  31. 8.6 Lantheus
  32. 8.6.1 Lantheus Company Information
  33. 8.6.2 Lantheus Business Overview
  34. 8.6.3 Lantheus Therapeutic Nuclear Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Lantheus Therapeutic Nuclear Drug Product Portfolio
  36. 8.6.5 Lantheus Recent Developments
  37. 8.7 Jubilant Radiopharma
  38. 8.7.1 Jubilant Radiopharma Company Information
  39. 8.7.2 Jubilant Radiopharma Business Overview
  40. 8.7.3 Jubilant Radiopharma Therapeutic Nuclear Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Jubilant Radiopharma Therapeutic Nuclear Drug Product Portfolio
  42. 8.7.5 Jubilant Radiopharma Recent Developments
  43. 8.8 International Isotopes
  44. 8.8.1 International Isotopes Company Information
  45. 8.8.2 International Isotopes Business Overview
  46. 8.8.3 International Isotopes Therapeutic Nuclear Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 International Isotopes Therapeutic Nuclear Drug Product Portfolio
  48. 8.8.5 International Isotopes Recent Developments
  49. 8.9 Curium Pharmaceuticals
  50. 8.9.1 Curium Pharmaceuticals Company Information
  51. 8.9.2 Curium Pharmaceuticals Business Overview
  52. 8.9.3 Curium Pharmaceuticals Therapeutic Nuclear Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Curium Pharmaceuticals Therapeutic Nuclear Drug Product Portfolio
  54. 8.9.5 Curium Pharmaceuticals Recent Developments
  55. 8.10 China Isotope & Radiation
  56. 8.10.1 China Isotope & Radiation Company Information
  57. 8.10.2 China Isotope & Radiation Business Overview
  58. 8.10.3 China Isotope & Radiation Therapeutic Nuclear Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 China Isotope & Radiation Therapeutic Nuclear Drug Product Portfolio
  60. 8.10.5 China Isotope & Radiation Recent Developments
  61. 8.11 Aurobindo Pharma
  62. 8.11.1 Aurobindo Pharma Company Information
  63. 8.11.2 Aurobindo Pharma Business Overview
  64. 8.11.3 Aurobindo Pharma Therapeutic Nuclear Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Aurobindo Pharma Therapeutic Nuclear Drug Product Portfolio
  66. 8.11.5 Aurobindo Pharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst